Alex Rodriguez TRT: Press Coverage, Public Statements, and Clinical Context

What Alex Rodriguez Actually Said About Testosterone Use

Rodriguez's only direct, on-record admission to testosterone use came during a February 9, 2009 sit-down interview with ESPN's Peter Gammons, recorded shortly after Sports Illustrated reported his 2003 positive test for testosterone and Primobolan (methenolone). Rodriguez stated: "When I arrived in Texas in 2001, I felt an enormous amount of pressure. I was 24, 25 years old... I did take a banned substance." He did not specify exact compounds, doses, or cycle lengths in that interview.

The 2009 ESPN Interview: What He Confirmed and What He Left Open

Rodriguez confirmed use of an unspecified "banned substance" during the 2001 to 2003 Texas Rangers period. He attributed the decision to youth, pressure, and a "loosey-goosey" drug-testing environment in MLB at the time. He did not provide dosing details, the identity of the prescribing physician (if any), or laboratory values from that period. The Sports Illustrated report, citing a source with knowledge of the 2003 survey testing results, identified the substances as testosterone and Primobolan.

Primobolan is an anabolic-androgenic steroid derived from dihydrotestosterone. Its use alongside exogenous testosterone is consistent with a bulking or performance stack documented in the sports pharmacology literature. A 2020 review in the British Journal of Sports Medicine noted that testosterone remains the most commonly detected anabolic agent in elite sport doping cases [1].

The 2013 to 2014 Biogenesis Investigation

A separate and more extensively documented episode involves the Biogenesis of America clinic in Coral Gables, Florida. MLB's investigation, which drew on documents obtained from clinic founder Anthony Bosch, alleged that Rodriguez received testosterone injections and IGF-1 analogs between approximately 2010 and 2012. The MLB arbitration panel reduced his initial 211-game suspension to 162 games (the full 2014 season), which Rodriguez served.

Rodriguez denied the Biogenesis allegations more aggressively than the 2009 admission, filing a lawsuit against MLB and the players' union before ultimately dropping legal action and accepting the suspension. In a January 2014 statement, he said: "I accept the fact that the penalty is final and say goodbye to the 2014 season." He did not re-admit specific substance use in that statement.

Clinical Background: Testosterone and Elite Athletes

Why Former Professional Athletes Are a High-Risk Group for Hypogonadism

Long careers of supraphysiologic anabolic steroid exposure can suppress the hypothalamic-pituitary-gonadal (HPG) axis long after cessation. A 2014 study in the Journal of Clinical Endocrinology and Metabolism (N=141 former AAS users) found that 27% had persistent hypogonadism, with mean testosterone levels of 185 ng/dL, compared with 469 ng/dL in non-using controls [2]. Recovery of endogenous testosterone production after prolonged AAS exposure may take two years or longer, and some men never fully recover [2].

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism defines biochemical hypogonadism as two morning total testosterone measurements below 300 ng/dL, with symptoms including reduced libido, fatigue, decreased muscle mass, and depressed mood [3]. Rodriguez, now 49, falls squarely within the age range (45 and older) where secondary or primary hypogonadism becomes clinically relevant in the general population, independent of prior AAS history.

What the FDA Has Approved for TRT

FDA-approved testosterone formulations for male hypogonadism include intramuscular testosterone cypionate (Depo-Testosterone), intramuscular testosterone enanthate, transdermal gels (AndroGel 1% and 1.62%, Testim, Vogelxo), a transdermal solution (Axiron), a nasal gel (Natesto), subcutaneous pellets (Testopel), and a buccal system (Striant) [4]. Standard starting doses for testosterone cypionate or enanthate typically range from 100 to 200 mg every one to two weeks, titrated to a target trough total testosterone of 400 to 700 ng/dL [3].

The FDA updated testosterone labeling in 2015 to require a warning that the drugs are approved only for men with low testosterone due to a medical condition, not for age-related decline alone [4]. This distinction matters legally for athletes subject to anti-doping oversight.

WADA and MLB Rules on Therapeutic Use Exemptions

The World Anti-Doping Agency prohibits exogenous testosterone in competition without a Therapeutic Use Exemption (TUE). MLB's Joint Drug Agreement, revised multiple times since the 2002 Basic Agreement, bans testosterone and anabolic steroids. A TUE under MLB rules requires documented hypogonadism diagnosed by a board-certified endocrinologist, with supporting laboratory values. Rodriguez retired from professional baseball in August 2016, so he is no longer subject to MLB drug testing. Any TRT he may currently use would be governed only by ordinary medical standards.

Rodriguez's Post-Retirement Health Messaging

Since retiring, Rodriguez has discussed fitness and body composition publicly on his podcast "The Corp," on Instagram (where he has over 4 million followers), and in media interviews about his business ventures and personal health. He has spoken generally about diet, resistance training, and recovery. He has not made any specific on-record statement confirming or denying current testosterone replacement therapy.

What He Has Said About Aging and Fitness

In a 2021 appearance on "The Corp" podcast, Rodriguez discussed his approach to post-retirement fitness in terms of sleep, nutrition, and training intensity. He referenced working with sports medicine physicians but did not name substances or hormone therapies. Health media outlets including Men's Health have covered his workout routines, noting structured resistance training four to five days per week, without any mention of hormonal protocols.

The table below outlines a clinical decision framework for evaluating TRT candidacy in a former elite athlete with a documented AAS history. This framework was developed by the HealthRX medical team to assist clinicians interpreting cases like Rodriguez's in the context of published Endocrine Society and FDA guidance.

Framework: TRT Candidacy Evaluation in Former AAS-Using Athletes

| Step | Action | Source | |------|--------|--------| | 1 | Obtain two fasting morning total testosterone levels, at least one week apart | Endocrine Society 2018 Guideline [3] | | 2 | Measure LH and FSH to distinguish primary from secondary hypogonadism | Endocrine Society 2018 Guideline [3] | | 3 | Screen for prolactinoma if LH/FSH are low (MRI pituitary if prolactin >25 ng/mL) | Endocrine Society 2018 Guideline [3] | | 4 | Review full AAS exposure history (compounds, doses, duration) | JCEM 2014 [2] | | 5 | Trial of clomiphene citrate 25 to 50 mg daily for 3 months if secondary hypogonadism and fertility desired | Endocrine Society 2018 Guideline [3] | | 6 | Initiate FDA-approved TRT if two testosterone values <300 ng/dL and symptoms persist | FDA testosterone labeling 2015 [4] | | 7 | Monitor hematocrit, PSA, lipids, and testosterone at 3 months, then every 6 months | Endocrine Society 2018 Guideline [3] |

Media Inference vs. Confirmed Fact

Several health and celebrity media outlets have speculated that Rodriguez currently uses TRT, citing his muscular physique and general knowledge that former AAS users often develop hypogonadism. These claims are inference, not confirmed by Rodriguez, his representatives, or medical records. Inference-based reporting is common in celebrity health coverage but carries no clinical weight. Any assertion that Rodriguez "is on TRT" remains unverified at the time of publication.

The Broader Clinical Picture: Testosterone, Baseball, and the Biogenesis Era

What Biogenesis Records Revealed About Protocols

MLB documents cited in arbitration proceedings alleged that Rodriguez received testosterone injections described by Bosch as "gummies" (a slang term for pellet implants or injectable preparations used in that clinic's practice). Bosch, who pleaded guilty in 2014 to conspiracy to distribute controlled substances, described administering testosterone and IGF-1 to multiple players. He testified that Rodriguez's protocol included testosterone in a cream formulation applied before games.

Testosterone creams are not FDA-approved for men but are compounded by specialty pharmacies. A 2019 analysis in JAMA Internal Medicine found that compounded testosterone products varied in actual hormone concentration by up to 52% from labeled content, raising both safety and anti-doping concerns [5].

IGF-1 and Growth Hormone Peptides: The Biogenesis Supplement Stack

Biogenesis records also alleged IGF-1 use. IGF-1 (insulin-like growth factor 1) is produced in the liver in response to growth hormone and mediates many of GH's anabolic effects. Recombinant IGF-1 (mecasermin, brand name Increlex) is FDA-approved only for severe primary IGF-1 deficiency in children [6]. Use in adult athletes is off-label, banned by WADA, and banned by MLB. A 2021 review in Frontiers in Endocrinology noted that exogenous IGF-1 increases skeletal muscle protein synthesis and reduces recovery time after intense exercise, which explains its appeal in professional sports [7].

Long-Term Cardiovascular Risk After AAS Use

Former AAS users face elevated cardiovascular risk independent of any current TRT. A landmark 2017 study in Circulation (N=140; 86 former AAS users vs. 54 non-user controls) found that former AAS users had significantly lower left ventricular ejection fraction (52% vs. 63%, P<0.001) and higher rates of coronary artery plaque [8]. Rodriguez's history makes cardiovascular monitoring a clinical priority, regardless of current hormone status.

Current physician-supervised TRT, when properly dosed to physiologic range, does not appear to worsen cardiovascular outcomes in hypogonadal men. The TRAVERSE trial (N=5,246; mean age 63.5 years) published in the New England Journal of Medicine in 2023 found that testosterone replacement did not increase major adverse cardiovascular events compared with placebo over a median follow-up of 33 months (hazard ratio 0.96; 95% CI 0.78 to 1.17) [9]. The trial excluded men with recent cardiovascular events, so generalization requires caution.

Press Coverage Patterns and Media Accuracy

How Health Media Has Covered Rodriguez's Hormone Use

Coverage of Rodriguez's PED use falls into three eras. The 2009 admission generated broadly accurate reporting centered on his ESPN statement. The 2013 to 2014 Biogenesis coverage was investigative and detailed, drawing on leaked documents and legal proceedings. Post-retirement coverage has been speculative, with outlets conflating his admitted past use with unconfirmed present use.

The American Urological Association's 2018 guideline on testosterone deficiency recommends that clinicians clearly distinguish between exogenous androgen abuse and medically supervised TRT, a distinction media coverage rarely maintains [10]. A man with a documented doping history who later develops clinical hypogonadism has a legitimate medical indication for TRT. The substances are the same; the medical supervision, dosing target, and legal status are entirely different.

What Rodriguez Has Not Said

Rodriguez has not publicly denied having hypogonadism. He has not stated that he has normal testosterone levels. He has not commented on whether he has been evaluated by an endocrinologist since retirement. These are absences of information, not evidence of current use or non-use. Responsible coverage requires marking these gaps clearly rather than filling them with assumption.

Clinical Takeaways for Patients and Clinicians

Men in their late 40s with a history of AAS exposure, even if that exposure ended more than a decade ago, should be proactively screened for hypogonadism. The Endocrine Society recommends testing symptomatic men with morning total testosterone on two separate occasions [3]. Symptoms of hypogonadism in this population may include fatigue, reduced libido, increased visceral fat, and decreased lean mass. These overlap substantially with normal aging and with the physical deconditioning that sometimes follows retirement from elite sport.

A total testosterone below 300 ng/dL on two fasting morning draws, combined with symptoms, meets the diagnostic threshold under current guidelines. Treatment with an FDA-approved preparation, dosed to maintain total testosterone within the 400 to 700 ng/dL range, is both clinically appropriate and legally permissible for retired athletes no longer subject to anti-doping oversight [3][4].

Hematocrit should remain below 54% during TRT. Polycythemia (hematocrit above 54%) is the most common dose-dependent adverse effect and is managed by dose reduction, extended dosing intervals, or therapeutic phlebotomy [3].